IDIOPATHIC HYPERSOMNIA
Clinical trials for IDIOPATHIC HYPERSOMNIA explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC HYPERSOMNIA trials appear
Sign up with your email to follow new studies for IDIOPATHIC HYPERSOMNIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for sleep disorder patients: ORX750 enters long-term safety trial
Disease control Recruiting nowThis study looks at the long-term safety and effects of a drug called ORX750 in people with narcolepsy (types 1 and 2) or idiopathic hypersomnia. About 90 participants who finished a previous ORX750 trial will take the drug openly for an extended period. Researchers will monitor …
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated May 26, 2026 11:26 UTC
-
New sleep disorder drug tested for Long-Term safety and effectiveness
Disease control Recruiting nowThis study looks at the long-term safety and how well the drug ALKS 2680 works for people with narcolepsy type 1, type 2, or idiopathic hypersomnia. It is for those who have already finished a related earlier study. Participants will take ALKS 2680 tablets and be monitored for si…
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE2, PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New orexin mimic could wake up sleep disorder treatment
Symptom relief Recruiting nowThis study tests a new drug called ORX750 (cleminorexton) that mimics a natural brain protein, orexin, which helps keep people awake. It is for adults with narcolepsy type 1, type 2, or idiopathic hypersomnia who struggle with severe daytime sleepiness. The goal is to see if the …
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Symptom relief
Last updated May 26, 2026 11:16 UTC
-
New pill aims to keep people with idiopathic hypersomnia awake
Symptom relief Recruiting nowThis study tests a new drug, ALKS 2680, to see if it safely reduces excessive daytime sleepiness in people with idiopathic hypersomnia, a condition that causes severe sleepiness without a clear cause. About 96 adults will take either the drug or a placebo daily for 8 weeks. The m…
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated May 22, 2026 14:03 UTC
-
Can a Low-Sodium drug help people who sleep too much?
Symptom relief Recruiting nowThis study looks at how low sodium oxybate, an FDA-approved drug for idiopathic hypersomnia, affects total sleep time in 30 adults aged 18-65. Participants will wear sleep monitors and special earbuds to track sleep. The goal is to see if the drug helps people sleep for long peri…
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 22, 2026 13:54 UTC
-
New drug TAK-360 could help extreme daytime sleepiness
Symptom relief Recruiting nowThis study tests a new medicine called TAK-360 for people with idiopathic hypersomnia (IH), a condition that causes extreme sleepiness even after lots of sleep. The drug works like a brain chemical called orexin that helps keep you awake. Researchers want to see if TAK-360 is saf…
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE2 • Sponsor: Takeda • Aim: Symptom relief
Last updated May 18, 2026 12:06 UTC
-
New hope for chronic sleepiness: experimental drug enters final testing phase
Symptom relief Recruiting nowThis study tests an experimental drug called HBS-301 in 248 adults with idiopathic hypersomnia, a condition causing severe daytime sleepiness, trouble waking up, and fatigue. Participants will receive either the drug or a placebo for several weeks to see if it reduces symptoms. T…
Matched conditions: IDIOPATHIC HYPERSOMNIA
Phase: PHASE3 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated May 14, 2026 12:03 UTC